Bristol Kidney Care Dr Albert Power Renal Medicine
Bristol Kidney CareDr Albert PowerRenal Medicine


Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort.

Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Annear N, Barratt J, Bingham C, et al; RaDaR consortium.

Lancet. 2024 Mar 30;403(10433):1279-1289. doi: 10.1016/


Empagliflozin in Patients with Chronic Kidney Disease.

The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al.

N Engl J Med. 2023 Jan 12;388(2):117-127.


Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.

Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators.

Kidney Int. 2023 Feb;103(2):391-402.


A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease.

Parker K, Hartemink J, Saha A, Mitra R, Lewis P, Power A, Choudhuri S, Mitra S, Thachil J.

J Nephrol. 2022 Nov;35(8):2015-2033.


An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.

Thomson PC, Mark PB, Robertson M, White C, Anker SD, Bhandari S, Farrington K, Jardine AG, Kalra PA, McMurray J, Reddan D, Wheeler DC, Winearls CG, Ford I, Macdougall IC; PIVOTAL Investigators and Committees.

Kidney Int Rep. 2022 May 18;7(8):1793-1801.


The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes.

Caskey FJ, Procter S, MacNeill SJ, Wade J, Taylor J, Rooshenas L, Liu Y, Annaw A, Alloway K, Davenport A, Power A, Farrington K, Mitra S, Wheeler DC, Law K, Lewis-White H, Ben-Shlomo Y, Hollingworth W, Donovan J, Lane JA.

Trials. 2022 Jun 27;23(1):532.


Research priorities for autosomal dominant polycystic kidney disease: a UK priority setting partnership.

Harris T, Bridges HR, Brown WD, O'Brien NL, Daly AC, Jindal BK, Mundy GS, Ong A, Power AJ, Sandford RN, Sayer J, Simms RJ, Wilson PD, Winyard PJD, Tarpey M.

BMJ Open. 2022 Jun 15;12(6):e055780.


Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.

Mark PB, Jhund PS, Walters MR, Petrie MC, Power A, White C, Robertson M, Connolly E, Anker SD, Bhandari S, Farrington K, Kalra PA, Tomson CRV, Wheeler DC, Winearls CG, McMurray JJV, Macdougall IC, Ford I; PIVOTAL Investigators.

Kidney360. 2021 Sep 16;2(11):1761-1769.


Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.

Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V; ASCEND-ND Study Group.

N Engl J Med. 2021 Dec 16;385(25):2313-2324.

Print | Sitemap
Bristol Kidney Care © Dr A. Power